Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

0.00%

20.5¢ resapp health limited

2020 commercialisation, page-612

First 612 Last

Share
Profile

Follow
SortedItOut

195 Posts.

40

20/11/20

15:42

Post #: 49024631
Share

Originally posted by rustys33: ↑
Although RAP's commercialization has been agonizingly slow - I think the big negative news is behind us. I just cant see how a company sitting on IP who has worked with or working with the following companies/organizations will amount to nothing;

Hospitals
- NHS (ongoing)
- Health Hub Doctors Morayfield (Queensland Health)
- Sana Linkum Lichtenberg
- Massachusetts General
- Texas Childrens Hospital
- Curtin

Telehealth
- Phenix
- WMA
- Medgate
- Health Engine
- Coviu
- Ilara

Charities
- Medecins Sans Frontieres
- Bill and Melinda Gates Foundation
- Diabetes Queensland

Pharma
- Sanofi
- RB
- AstraZeneca

Other
- DARPA / Lockhead Martin
- Creosphere
- University of Queensland

Obviously, some of those have worked out better than others, but most are still bubbling along in some respect. These are just the ones we know of.

I think we are still a way away from booking some serious revenue and probably over a year until we get back into the 20c range as it appears many long term hot copperites have given up (not so much the biggest investors).

What im looking forward to is;

- FDA approval of sleepcheck
- FDA approval of ResAppDx (after we have real-world data)
- Further European telehealth deals
- Asian (specifically Singapore) telehealth deal
- Results of Ilara study and in-clinic adoption
- NHS study results and use of the device in a clinical setting (probably not revenue-generating initially)
- Integration of ResAppDX with Health Direct (the best candidate for significant revenue short term)
- Paid use of ResAppDX in respiratory clinics
- COPD results and commercialization
- Further collaboration with clinical studies with the 'cough counter product'
- WMA launch an revenue generation
- RB direct to consumer product launch (the big unknown and given the zero sp action has not been factored into the share price)

It's evident this company can attract interest from numerous health organisations and when the revenue comes, it will unlock all of the phase 2 products which are pipe dreams currently.

Yeah, they have stuffed things up and communication often lacks frequency and detail, but there is proof that the product is real and sort after. This type of technology is the future, and outside of the established tech-oligarchs, it could be argued that RAP is in a pretty solid position and only valued at $70 million.
Expand
Agree Rusty, lots of irons in the fire, one must strike gold shortly given the quality of interested from well respected companies/medical institutions.

FYI what I'm waiting on currently in lead in to the general EOY shutdown
22nd Nov Health day batch 1 summary, plug and play
1 26nd Nov AGM meeting
2 1st Dec Ends the 3 month extension in Morayfield, paper to come after?
3 18th Dec MOU 6 months is up with RB

RAP Price at posting: 9.1¢ Sentiment: Hold Disclosure: Held
27 Upvote

5 Great analysis

Reply

Top Stories

Time for retail therapy buying in the shopping Scentre for hot stocks

End of FY is a time to juggle wins, losses and capital gains taxes

SS1

Sun Silver submits US$60M Silver Paste Funding Application to US DoE

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Eurozone-based companies find new ways to secure a regional lithium supply